Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-755 for acute ischemic stroke
jRCT2071260013Phase 2Recruiting
- Sponsor
- Takeda
- Start
- May 2026
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing TAK-755 with Placebo (2 arms). Primary endpoint: Percentage of participants who develop symptomatic intracranial hemorrhage. Started May 2026; status: recruiting.
02
Drugs
Apadamtase alfa
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on jRCT2071260013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260013.